The phagocytic vitronectin receptor (αvβ3) can be blocked with RGD-containing peptides, and the nasal delivery of these peptides provides substantial protection in rat models of ischemic stroke [66,87]. The gene discussed is ITGAV; the disease is ischemic stroke.